Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Eastern Cooperative Oncology Group
Modality
UNKNOWN
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
56High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT00006223CT.gov flt3L in Treating Patients With Acute Myeloid Leukemia | — | Completed | — | — | — |
NCT00006225CT.gov Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Recombinant Flt3 Ligand (this asset) | Eastern Cooperative Oncology Group | P3 | B · 59 |
| Vincristine Sulfate | Inhye Ahn | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BB |
| Pegaspargase | Dana-Farber Cancer Institute | P3 | BB |
| Nivestim | Hospital General de Mexico | P4 | BB |
| Idarubicin | Affiliated Hospital of Nantong University | P3 | BB |
| Daunomycin | Richard Stone, MD | P3 | BB |
| Mercaptopurine Anhydrous | Dana-Farber Cancer Institute | P3 | BB |
| Busulfanum | National Cancer Institute (NCI) | P4 | BB |
+42 more in the Leukemia cohort
Other indications for Recombinant Flt3 Ligand
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cutaneous Melanoma | — | P2 | B · 61 |
| Mucosal Melanoma | — | P2 | B · 57 |
| Ocular Melanoma | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Recombinant Flt3 Ligand in Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/recombinant-flt3-ligand-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →